Martin Schönharting

Title: Martin Schönharting: Innovator in Immunological Therapies

Introduction

Martin Schönharting is a notable inventor based in Taunusstein, Germany. He has made significant contributions to the field of immunology through his innovative patents. With a total of 2 patents, Schönharting's work focuses on combination therapies that address immune diseases.

Latest Patents

Schönharting's latest patents include a combination preparation that contains cyclosporin A, FK506, or rapamycin along with a xanthine derivative. This combined preparation is designed for the therapy of immune diseases. Another notable patent involves a combination preparation comprising a compound with phosphodiesterase-inhibiting action and a compound that reduces biologically effective intracellular calcium content, making it suitable for treating immunological diseases.

Career Highlights

Throughout his career, Martin Schönharting has worked with prominent companies in the pharmaceutical industry. He has been associated with Hoechst Aktiengesellschaft and Aventis Pharma Deutschland GmbH, where he contributed to the development of innovative therapeutic solutions.

Collaborations

Some of his notable coworkers include Stefan Müllner and Peter Zabel, who have collaborated with him on various projects in the field of immunology.

Conclusion

Martin Schönharting's contributions to immunological therapies through his patents and collaborations highlight his role as an influential inventor in the pharmaceutical industry. His work continues to impact the treatment of immune diseases significantly.